Anacardio

AnaCardio is developing novel drugs to treat heart failure. First in class Ca2+ sensitizing myotrope. AnaCardio has generated proof of concept with peptide X in HFrEF patients and has partnered with Helsinn to license an oral peptide analogue.

AnaCardio joined NOME in 2022 and is headed by Lars Lund MD, Ph.D. and Patrik Strömberg Ph.D., MBA.

Company details

Website

Anacardio.com

More companies

Adamant HealthNOME2024-07-09T12:33:39+00:00

Adamant Health
Adamant Health

Medical Devices
Alder TherapeuticsNOME2024-07-09T12:27:31+00:00

Alder Therapeutics
Alder Therapeutics

Therapeutics
CSW TherapeuticsNOME2024-07-09T12:20:00+00:00

CSW Therapeutics
CSW Therapeutics

Medical Devices
Inform LifeNOME2024-07-09T12:35:35+00:00

Inform Life
Inform Life

Other
Reccan DiagnosticsNOME2024-07-09T12:03:38+00:00

Reccan Diagnostics
Reccan Diagnostics

Diagnostics
Fuse VectorsNOME2024-07-09T11:39:06+00:00

Fuse Vectors
Fuse Vectors

Therapeutics
MetsystemNOME2024-05-30T11:11:02+00:00

Metsystem
Metsystem

Digital Health
Droplet IVNOME2024-04-15T08:52:38+00:00

Droplet IV
Droplet IV

Medical Devices

VIEW ALL PROJECTS

Anacardio

Project Description

Anacardio

Company details

Website

More companies